Navidea Biopharmaceuticals Announces Addition to Major Indexes on Tel Aviv Stock Exchange
September 28 2015 - 7:30AM
Business Wire
- Expands access to investors for NAVB shares
listed on NYSE and TASE -
Navidea Biopharmaceuticals Inc., (NYSE MKT:NAVB), a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents, today announced that Navidea’s common
stock, which began trading on the Tel-Aviv Stock Exchange ("TASE")
on September 8, 2015, will be included, effective October 6, 2015,
in the following major TASE indexes: TA-100, TA-75, TA-Composite,
TA-Biomed, TA-BlueTech and TA-Tech-Elite.
Navidea is, and will remain, subject to the applicable rules and
regulations of NYSE MKT-listed companies and the U.S. Securities
and Exchange Commission. Under Israel's Dual Listing Law,
U.S.-listed companies may also list on the TASE without any
additional regulatory requirements. Trading on the TASE occurs
Sunday through Thursday from 8:30 am to 4:30 pm Israel time, except
on TASE trading holidays, and trading on the NYSE MKT occurs Monday
through Friday, 9:30 am to 4:00 pm Eastern Time, except on NYSE
holidays. The TASE Clearing House is electronically linked to the
Depository Trust Company, a subsidiary of the Depository Trust
& Clearing Corporation, to automate the cross-border settlement
of shares listed on both the TASE and a U.S. Exchange.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150928005737/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024